- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Additional Pricing Considerations
During this segment, Bruce Feinberg, DO; Scott Gottlieb, MD; Brian Kiss, MD; Michael Kolodziej, MD; and Ted Okon, MBA, discuss factors that influence prices for oncology drugs as well as for medications for other disease states.
With regard to Sovaldi, the hepatitis C patient population is relatively large compared with the patient populations for certain cancers, notes Dr Gottlieb. Thus, pricing changes for Sovaldi have a large financial impact due to the number of patients infected with hepatitis C.
The patient populations eligible for cell-based and gene therapy—based therapies that are being developed in oncology may be relatively small, comments Dr Gottlieb. However, these treatments are likely to be associated with extremely high costs, and discussions about how to finance treatment and reduce costs are necessary.
Mr Okon and Drs Feinberg, Kiss, and Kolodziej reflect on how volume and competition within the market impacted the cost of Sovaldi and discuss how volume and competition may impact the pricing of new oncology agents as they enter the market.
Dr Kolodziej highlights additional considerations that will influence future financial incentives and reimbursements, and the costs of emerging treatment options. For example, he suggests that innovative treatment options and more competition within the market may have a substantial impact.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
